#Endocrine | #Metabolic | #TripleAgonist

GLP3-R — Research Overview (RUO)

GLP3-R is a synthetic “tri-agonist” peptide that targets three distinct receptors: the Glucagon Receptor (GCGR), Glucose-dependent Insulinotropic Polypeptide Receptor (GIPR), and Glucagon-like Peptide-1 Receptor (GLP1-R). This triple-action mechanism represents the frontier of metabolic research, aiming to maximize energy expenditure and weight-loss efficacy in experimental models.

Compound Name

GLP3-R

Mechanism

Triple Agonist (GCG / GIP / GLP-1)

Structure

Linear peptide with C20 fatty diacid moiety

Primary Research Focus

Maximal Metabolic Efficiency & Obesity

Regulatory Status

Research Grade Material (RUO)

Chemical Formula

C₂₂₁H₃₄₂N₄₆O₆₈

Molecular Weight

~4731.33 g/mol

Sequence Length

39 Amino Acids

Structure Note

Features a GIP-based backbone sequence with key substitutions to confer balanced activity at GLP-1 and Glucagon receptors. Attached C20 fatty acid promotes albumin binding.

Lyophilized peptide is stable at −20 °C. Protect from moisture and light.

Soluble in sterile bacteriostatic water. Handle with care to prevent aggregation.

Sequence Length

Triple Receptor Agonism (GCG / GIP / GLP-1)

GLP3-R explores the concept that adding Glucagon receptor (GCGR) activity to the GIP/GLP-1 backbone enhances energy expenditure.

Glucagon Component: Unlike pure GLP-1 agonists which reduce food intake, GCGR activity is hypothesized to increase metabolic rate and lipolysis in the liver.
Balanced Signaling: Research aims to determine the optimal ratio of receptor activation to maximize weight loss while mitigating the hyperglycemic risk of glucagon.

Hepatic Health & MASLD / MASH Models

A major application is in models of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Liver Fat Reduction: Direct GCGR stimulation promotes mitochondrial fatty acid oxidation in hepatocytes, rapidly clearing liver fat.
De-Lipidation: Studies tracking the resolution of steatosis and inflammation (MASH) in diet-induced obese mice.

Obesity & Extreme Weight Regulation

GLP3-R demonstrates the highest efficacy in weight-loss models among the incretin class.

Synergistic Mechanisms: Combining satiety (GLP-1/GIP) with increased thermogenesis (Glucagon) to produce profound weight reduction in rodent models.
Lipid Mobilization: Measuring accelerated breakdown of white adipose tissue depots.

Glycemic Control Dynamics

Despite the inclusion of glucagon (which typically raises blood sugar), GLP3-R improves glycemic control.

Insulinotropic Effect: Strong GIP and GLP-1 activity overpowers the glycogenolytic effect of glucagon, resulting in net improvement in HbA1c markers in diabetic models.
Insulin Sensitivity: Secondary improvements due to massive weight loss and liver de-lipidation.

Research Limitations

Cardiovascular Heart Rate: Glucagon receptor activation can be chronotropic (increasing heart rate). Monitoring cardiovascular parameters is crucial in animal studies.
Complexity: Dissecting the individual contribution of three different receptors in a single-molecule study requires complex knockout models or receptor-specific antagonists.

Key Scientific References

Gault, V. A., et al. (2023) “Tri-agonist efficacy in metabolic disease: The role of glucagon.” Journal of Endocrinology.
Knerr, P. J., et al. (2022) “Discovery of GLP-3 R, a Potent and Long-Acting GIP, GLP-1, and Glucagon Receptor Triagonist.” Cell Metabolism.
Jastreboff, A. M., et al. (2023) “Triple-Hormone-Receptor Agonist for Obesity — A Phase 2 Trial.” New England Journal of Medicine.
Finan, B., et al. (2015) “A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.” Nature Medicine.

The compound listed below is referenced in research contexts related to the mechanisms discussed in this article.

GLP3-R is a chemical reference standard intended strictly for in-vitro and laboratory research applications (e.g., receptor binding studies, metabolic modeling). It is not a drug, dietary supplement, or weight-loss product for human consumption. It is not intended for injection or therapeutic use. All handling must be performed by qualified professionals in a laboratory setting.

GLP3-R — Research Overview (RUO)

Compound Name

Mechanism

Structure

Primary Research Focus

Regulatory Status

Chemical Formula

Molecular Weight

Sequence Length

Structure Note

Sequence Length

Age Verification Required

GLP2-T

Thymosin Alpha-1 (TA1)

Tesamorelin

TB-500

SS-31

Semax

Selank

GLP3-R

PT-141